Chugai debuts Evrysdi Dry Syrup for SMA in Japan

12 August 2021

Japanese drugmaker Chugai (TYO: 4519) says it has launched Evrysdi (risdiplam) Dry Syrup 60mg for the treatment of spinal muscular atrophy (SMA). Evrysdi had been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) on June 23, 2021, and was listed on the national health insurance (NIH) reimbursement price list this week.

“We are very pleased to launch Evrysdi as the first at home drug for the treatment of SMA,” said Dr Osamu Okuda, president and chief executive of Chugai, which is majority-owned by Swiss pharm giant Roche (ROG: SOX). “Evrysdi has shown efficacy in a wide age range from babies to adults, and will offer at-home dosing. We are committed to promoting appropriate use of Evrysdi so that we may deliver unprecedented value to people with SMA and their families through this new therapeutic option,” he added.

Clinical backing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK